Meanwhile, Enadenotucirev (EnAd), a chimeric adenovirus, takes a different approach by downregulating HIF-1α during late-stage infection, thereby reducing VEGF and other pro-angiogenic factors, disrupting tumor vasculature, and enhancing T-cell infiltration into hypoxic regions. The gene discussed is VEGFA; the disease is neoplasm.